...the strategy makes sense, phase-2B with lots of shots on goal. It's an unwieldy and unduly expensive program, IMO. I was expecting a simpler plan. CNAT doesn't have the financial resources to conduct so many phase-2b trials, so (absent a partner), there's a considerable amount of dilution coming. I sold my remaining shares.